The Global Liquid Biopsy Market Size is projected to reach around US$ 10.08 Billion by 2030, according to the report. Liquid biopsy is a revolutionary diagnostic approach transforming cancer detection and tracking. Unlike traditional tissue biopsies, it includes studying circulating tumour components, together with DNA, RNA, or proteins, in physical fluids like blood. This non-invasive technique gives valuable insights right into a patient's molecular profile, bearing in mind early cancer detection, treatment selection, and tracking of remedy reaction. Liquid biopsy is in particular critical for detecting minimal residual disease and understanding tumour heterogeneity. Its versatility extends across numerous cancer sorts, providing a promising tool for personalized medicine. With ongoing improvements, liquid biopsy holds substantial ability to enhance precision oncology and improve patient results.
Moreover, liquid biopsy is a progressive cancer diagnostic that outperforms conventional tissue biopsies by dynamically reading circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) in blood, revealing vital genetic heterogeneity for personalized remedy. It gives insights into tumour mutations, gene expression, and biomarkers, guiding tailor-made remedy for greater efficacy, decreased side effects, and early resistance detection. The market expands as healthcare carriers understand its ability for optimizing techniques, monitoring disorder development, and enhancing patient outcomes through real-time insights into tumour dynamics, aligning with the growing emphasis on personalized therapy in oncology.
Further, the global liquid biopsy market is characterized by collaborations among biotechnology agencies, pharmaceutical companies, and research institutions. For example, collaboration of Thermo Fisher Scientific with Guardant Health broadened a companion diagnostic test primarily based on Guardant's liquid biopsy platform, LUNAR-ID. This test is designed to discover particular genetic mutations in patients with lung cancer that might guide treatment selections. These collaborations foster research and development efforts, riding the commercialization of revolutionary liquid biopsy products. As a result, the market is predicted to retain its boom trajectory, with ongoing research, technological advancements, and a growing recognition of the advantages of liquid biopsy in cancer management contributing to its sustained growth in the years yet to come. Hence, the Liquid Biopsy Market was worth US$ 3.73 Billion in 2023.
Liquid biopsy is an alternative method for cancer (Lung, Breast, Colorectal, Prostate, Liver, and Other) detection that allows for screening, therapy selection, and disease prognosis. It's beneficial for patients who cannot undergo invasive tumor biopsies. High prevalence and demand for minimally invasive therapies drive the cancer liquid biopsy market.
Favorable guidelines expedite product approval, enhancing patient accessibility. Leading biotech and pharmaceutical businesses, coupled with educational-enterprise collaborations, accelerate technological development. Advocacy efforts enlarge patient demand, aligning with the U.S.'s data-driven, customized medicine consciousness. Substantial investments in liquid biopsy infrastructure underscore the nation's dedication to technological advancement on this subject.
F. Hoffmann-La Roche Ltd. (Roche), a global healthcare leader renowned for pioneering cancer diagnostics and therapeutics, recently marked a significant milestone in January 2023. The company announced the expansion of the cobas® EGFR Mutation Test CDx label, granting it a unique status as the first and only liquid biopsy test with a broad indication covering all stages of non-small cell lung cancer (NSCLC). This expanded label empowers oncologists with a valuable tool for guiding treatment decisions across all stages of NSCLC, reflecting Roche's commitment to advancing innovative solutions in cancer care.
This research report provides a detailed and comprehensive insight of the Global Liquid Biopsy Industry.
Liquid Biopsy Market is expected to grow at a CAGR of 15.26% between 2024 and 2030
The surge in cancer instances is markedly related to a growing older populace, with improved vulnerability to specific cancers as individual’s age. Factors encompass accumulated genetic mutations, a waning immune system's decreased capability to cast off mutated cells, and prolonged exposure to environmental cancer agents. Lifestyle picks, which includes unhealthy diets, tobacco smoking, immoderate alcohol intake, no physical activity, and obesity, considerably contribute to cancer danger. Comprehensive prevention strategies need to deal with age-related vulnerabilities and modifiable lifestyle factors to efficiently mitigate cancer risks in diverse populations.Moreover, liquid biopsy is a progressive cancer diagnostic that outperforms conventional tissue biopsies by dynamically reading circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) in blood, revealing vital genetic heterogeneity for personalized remedy. It gives insights into tumour mutations, gene expression, and biomarkers, guiding tailor-made remedy for greater efficacy, decreased side effects, and early resistance detection. The market expands as healthcare carriers understand its ability for optimizing techniques, monitoring disorder development, and enhancing patient outcomes through real-time insights into tumour dynamics, aligning with the growing emphasis on personalized therapy in oncology.
Further, the global liquid biopsy market is characterized by collaborations among biotechnology agencies, pharmaceutical companies, and research institutions. For example, collaboration of Thermo Fisher Scientific with Guardant Health broadened a companion diagnostic test primarily based on Guardant's liquid biopsy platform, LUNAR-ID. This test is designed to discover particular genetic mutations in patients with lung cancer that might guide treatment selections. These collaborations foster research and development efforts, riding the commercialization of revolutionary liquid biopsy products. As a result, the market is predicted to retain its boom trajectory, with ongoing research, technological advancements, and a growing recognition of the advantages of liquid biopsy in cancer management contributing to its sustained growth in the years yet to come. Hence, the Liquid Biopsy Market was worth US$ 3.73 Billion in 2023.
Kits in liquid biopsy have numerous benefits, driving high global demand in the global liquid biopsy market
By product, the global liquid biopsy market has been distinguished into Kits & Reagents, Platforms & Instruments, and Services. Liquid biopsy kits, known for simplicity, are needed in medical labs and research. Their high sensitivity detects minute cancer cell amounts in blood, crucial for rare cases. High specificity prevents fake positives, distinguishing cancers from normal cells. Cost-effectiveness makes them low-cost. Their vast applicability throughout cancer supports flexible analysis and tracking. Amidst growing call for non-invasive cancer prognosis, liquid biopsy's growth is fueled, solidifying the pivotal role of those kits in meeting healthcare demands.High share of cancer therapeutic applications in the global liquid biopsy market is driven by its ability to provide real-time insights into tumour dynamics
By application, the global liquid biopsy market has been divided into Cancer Therapeutic Application, Reproductive Health, and Other Therapeutic. Liquid biopsy transforms cancer care through non-invasive tracking and early detection of resistance. Analyzing ctDNA or CTCs in blood allows well timed changes to remedy, supported by customized decisions through genomic profiling. The approach excels in detecting minimum residual ailment, allowing proactive interventions to prevent recurrence. So, liquid biopsy optimizes treatment, tailors treatment options, and complements real-time records for advanced patient outcomes. Its non-invasive nature, regarding a simple blood draw, boosts compliance and facilitates repeated sampling, decreasing soreness and risks associated with conventional biopsies.Liquid biopsy is an alternative method for cancer (Lung, Breast, Colorectal, Prostate, Liver, and Other) detection that allows for screening, therapy selection, and disease prognosis. It's beneficial for patients who cannot undergo invasive tumor biopsies. High prevalence and demand for minimally invasive therapies drive the cancer liquid biopsy market.
Circulating tumour cells (CTCs) are continuously growing in the global liquid biopsy market
By circulating biomarker, the global liquid biopsy market has been broken up into Circulating Tumour Cell, Circulating Tumour DNA, Cell-free DNA (cfDNA), Extracellular Vesicles, and Other Biomarkers. Advances in CTC detection, the use of microfluidic devices, antibody-based strategies, and sequencing, enhance uncommon CTC evaluation precision. This progress deepens understanding of CTC biology, revealing molecular profiles, heterogeneity, and metastatic mechanisms. This knowledge informs innovative diagnostic and healing strategies. CTCs are pivotal prognostic and predictive biomarkers, imparting insights into cancer recurrence, metastasis, and treatment response. Their excessive sensitivity makes them powerful indicators of minimal residual disorder, enabling proactive interventions to prevent or postpone recurrence after preliminary treatment.Point-of-care testing (POCT) is gaining significant traction in the global liquid biopsy market due to its ability to provide rapid and accurate testing at the point of care
By end-user, the global liquid biopsy market has been fragmented into Hospitals, Diagnostic Laboratories, Point-of-care Testing, Academic Institutes, and Others. POCT transforms liquid biopsy, imparting rapid, precise analysis at the patient's bedside for real-time diagnostic insights, prompting fast remedy selections. This improves patient care, lowering hospital stays and healthcare costs whilst decentralizing services for broader accessibility. POCT enhances convenience by doing away with travel needs and multiple testing visits, contributing to patient satisfaction. Integration with electronic health facts streamlines data change, and technological improvements enhance price-effectiveness, expanding POCT's appeal across clinical settings. Also, POCT holds ability for early cancer detection, aligning with personalised medicine trends and overcoming challenges in traditional liquid biopsy techniques.United States holds a dominant position in the global liquid biopsy market
By country, the global liquid biopsy market has been divided into United States, Canada, Mexico, Brazil, United Kingdom, Germany, France, Italy, Spain, Netherlands, China, Japan, India, South Korea, Australia, United Arab Emirates, South Africa, and Rest of the World. The U.S. stands as a liquid biopsy innovation hub, pushed by robust healthcare infrastructure and a robust research commitment. With 1.9 million annual cancer cases, there may be a heightened call for early detection and treatment monitoring through liquid biopsy.Favorable guidelines expedite product approval, enhancing patient accessibility. Leading biotech and pharmaceutical businesses, coupled with educational-enterprise collaborations, accelerate technological development. Advocacy efforts enlarge patient demand, aligning with the U.S.'s data-driven, customized medicine consciousness. Substantial investments in liquid biopsy infrastructure underscore the nation's dedication to technological advancement on this subject.
Key Players
F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson, Biocept Inc., Guardant Health, Illumina, Inc., Laboratory Corporation of America Holdings, QIAGEN N.V, and Exact Sciences Corporation, are the major competitors in the global liquid biopsy market.F. Hoffmann-La Roche Ltd. (Roche), a global healthcare leader renowned for pioneering cancer diagnostics and therapeutics, recently marked a significant milestone in January 2023. The company announced the expansion of the cobas® EGFR Mutation Test CDx label, granting it a unique status as the first and only liquid biopsy test with a broad indication covering all stages of non-small cell lung cancer (NSCLC). This expanded label empowers oncologists with a valuable tool for guiding treatment decisions across all stages of NSCLC, reflecting Roche's commitment to advancing innovative solutions in cancer care.
This research report provides a detailed and comprehensive insight of the Global Liquid Biopsy Industry.
Product - Liquid Biopsy Market breakup from three viewpoints:
- Kits & Reagents
- Platforms & Instruments
- Services
Application - Liquid Biopsy Market breakup from three viewpoints:
- Cancer Therapeutic Application
- Reproductive Health
- Other Therapeutic
Circulating Biomarkers - Liquid Biopsy Market breakup from three viewpoints:
- Circulating Tumour Cell
- Circulating Tumour DNA
- Cell-free DNA
End-User - Liquid Biopsy Market breakup from five viewpoints:
- Hospitals
- Diagnostic Laboratories
- Point-of-care Testing
- Academic Institutes
- Others
Country - This report covers the 18 Countries Liquid Biopsy Market
- Americas
- United States
- Canada
- Mexico
- Brazil
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Asia - Pacific
- China
- Japan
- India
- South Korea
- Australia
Middle East & Africa
- United Arab Emirates
- South Africa
Rest of the World
All companies have been covered from 3 viewpoints:
- Overview
- Recent Development
- Revenue
Company Analysis
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories
- Thermo Fisher Scientific Inc.
- Johnson & Johnson
- Biocept Inc.
- Guardant Health
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- QIAGEN N.V.
- Exact Sciences Corporation
Table of Contents
1. Introduction2. Research & Methodology3. Executive Summary5. Global Liquid Biopsy Market
4. Market Dynamics
6. Market Share Analysis - Global Liquid Biopsy Market
7. Product - Global Liquid Biopsy Market
8. Application - Global Liquid Biopsy Market
9. Circulating Biomarker - Global Liquid Biopsy Market
10. End User - Global Liquid Biopsy Market
11. Country - Global Liquid Biopsy Market
12. Porter’s Five Analysis - Global Liquid Biopsy Market
13. SWOT Analysis - Global Liquid Biopsy Market
14. Company Analysis
List of Figures
List of Tables
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories
- Thermo Fisher Scientific Inc.
- Johnson & Johnson
- Biocept Inc.
- Guardant Health
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- QIAGEN N.V.
- Exact Sciences Corporation
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 230 |
| Published | January 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 3.73 Billion |
| Forecasted Market Value ( USD | $ 10.08 Billion |
| Compound Annual Growth Rate | 15.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
